Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 103

Results For "NCEs"

2671 News Found

Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects
People | July 14, 2025

Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects

Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.


Evonik opens new medical device center in Shanghai
News | July 12, 2025

Evonik opens new medical device center in Shanghai

The company’s largest center for medical device applications, serving the entire Asian market


Indegene launches NEXT Medical Writing Automation
News | July 12, 2025

Indegene launches NEXT Medical Writing Automation

To streamline complex medical writing workflows with GenAI


IMCD and Friesland Campina Professional expand distribution agreement across EMEA
Supply Chain | July 11, 2025

IMCD and Friesland Campina Professional expand distribution agreement across EMEA

Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers


Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products
News | July 11, 2025

Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products

Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content


EMA and HMA to strengthen Anti-D Immunoglobulin supply chain
News | July 08, 2025

EMA and HMA to strengthen Anti-D Immunoglobulin supply chain

These medicines are essential in preventing RhD immunisation during pregnancy


Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB
Policy | July 07, 2025

Dr. Jitendra Singh inaugurates 'National Biobank' at CSIR-IGIB

CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders


Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer
Clinical Trials | July 06, 2025

Imfinzi approved in the EU as first and only perioperative immunotherapy for muscle-invasive bladder cancer

Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone


atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression
News | July 04, 2025

atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression

atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.